Pfizer initiated phase 2/3 study of novel COVID-19 oral treatment in pediatric participants
On Mar. 9, 2022, Pfizer announced that it had initiated a Phase 2/3 study, EPIC-PEDS (Evaluation of Protease…
-
-
University of Oxford reported brain regions related to smell show decline following mild COVID-19
On Mar. 7, 2022, researchers from the University of Oxford have used data from UK Biobank participants to…
-
Possible case of deer-to-human SARS-CoV-2 transmission
On Mar. 3, 2022, a study carried out in southwestern Ontario identified a highly mutated variant of SARS-CoV-2…
-
Sorrento announced COVISHIELD antibody nasal drops prevent productive SARS-CoV-2 infections
On Mar. 2, 2022, Sorrento Therapeutics announced that new preclinical results demonstrated that pretreating an animal with intranasal…
-
Possible case of deer-to-human SARS-CoV-2 transmission
On Feb. 25, 2022, researchers announced that wildlife reservoirs of SARS-CoV-2 can lead to viral adaptation and spillback…
-
Medicago and GSK announced approval by Health Canada of COVIFENZ, an adjuvanted plant-based COVID-19 vaccine
On Feb. 24, 2022, Medicago and GlaxoSmithKline announced that Health Canada had granted approval for COVIFENZ, COVID-19 vaccine,…
-
University of Oxford researchers created largest ever human family tree
On Feb. 24, 2022, researchers from the University of Oxford have used data from UK Biobank participants to…
-
Biotechnology | COVID-19 | Infectious Disease | NIH | Vaccine | WHO
Novavax and Serum Institute of India announced first EUA of COVID-19 vaccine in adolescents =12 to <18 in India
On Mar. 22, 2022, Novavax and Serum Institute of India announced that the Drugs Controller General of India…
-
Health Canada authorized Novavax COVID-19 vaccine
On Feb. 17, 2022, Novavax announced that Health Canada had granted authorization for Nuvaxovid COVID-19 Vaccine (Recombinant protein,…
-
Therapeutic Goods Administration of Australia authorized Moderna’s Covid-19 vaccine in children (6-11 Years)
On Feb. 16, 2022, Moderna announced that the Therapeutic Goods Administration in Australia had granted provisional registration for…
-
Singapore Health Sciences Authority issued interim authorization for Novavax COVID-19 vaccine
On Feb. 14, 2022, Novavax announced that the Singapore Health Sciences Authority (HSA) had issued interim authorization for…
-
Research scientists identified vulnerable site on multiple coronaviruses that could be targeted to prevent future pandemics.
On Feb. 10, 2022, Scripps Research announced that the COVID-causing virus SARS-CoV-2 harbors a vulnerable site at the…
-
Study suggested COVID-19 vaccines do not reduce fertility
On Feb. 8, 2022, a research team led at Boston University School of Public Health reported on links…
-
How sneezing hamsters sparked a COVID outbreak in Hong Kong
On Feb. 4, 2022, pet hamsters probably carried the Delta variant of SARS-CoV-2 into Hong Kong and sparked…
-
CDC’s ACIP issued recommendation for use of Moderna COVID-19 vaccine in adults aged =18 years
On Feb. 4, 2022, the Advisory Committee on Immunization Practices (ACIP) issued a standard recommendation for use of…
-
Research collaboration launched to focus on repurposing existing anti-viral therapies to treat COVID-19
On Feb. 4, 2022, a new ﾣ1.6m collaborative project was launched to rapidly identify new treatments for COVID-19….
-
UK MHRA granted Conditional Marketing Authorization for Novavax COVID-19 vaccine in Great Britain
On Feb. 3, 2022, Novavax announced that the Medicines and Healthcare products Regulatory Agency had granted conditional marketing…
-
T2 Biosystems T2SARS-CoV-2 panel detects Omicron subvariants
On Feb. 3, 2022, T2 Biosystems announced that its T2SARS-CoV-2 Panel detected Omicron COVID-19 subvariants BA.1, BA.2, and…
-
New Zealand’s Medsafe granted provisional approval for Novavax’ COVID-19 vaccine
On Feb. 3, 2022, Novavax announced that New Zealand’s Medsafe had been granted provisional approval of NVX-CoV2373, Novavax’…
-
Novavax submitted request to U.S. FDA for Emergency Use Authorization of COVID-19 vaccine
On Jan. 31, 2022, Novavax announced that it had submitted a request to the U.S Food and Drug…
-
Merck and Ridgeback’s Molnupiravir, investigational antiviral COVID-19 medicine, demonstrated activity against Omicron variant
On Jan. 28, 2022, Merck and Ridgeback Biotherapeutics announced data from six preclinical studies demonstrating that molnupiravir, an…
-
Cocrystal Pharma selected two lead antiviral drug candidates for COVID-19 oral drug program
On Jan. 27, 2022, Cocrystal Pharma announced that it had selected two investigational novel antiviral drug candidates for further…
-
Hyperimmune intravenous immunoglobulin does not improve outcomes for adults hospitalized with COVID-19
On Jan. 27, 2022, NIAID announced that a clinical trial found that the combination of remdesivir plus a…
-
International research team found nine new coronavirus species
On Jan. 26, 2022, a former University of British Columbia post-doctoral research fellow led an international research team…
-
Cepheid received Health Canada license for Xpert Xpress CoV-2/Flu/RSV plus
On Jan. 25, 2022, Cepheid announced that Health Canada had issued Cepheid a medical device license for Xpert…
-
USDA announced study with zoos and aquariums to identify animal species susceptible to SARS-CoV-2
On Jan. 25, 2022, the U.S. Department of Agricultureﾒs National Veterinary Services Laboratories announced a study with zoos…
-
University of Missouri researchers identified mutations of Delta, Delta Plus variants
On Jan. 25, 2022, researchers at the University of Missouri announced they had identified the highly prevalent, specific…
-
Report published in PNAS detailed spread and evolution of SARS-CoV-2 in white-tailed deer across the U.S.
On Jan. 25. 2022, a report published in PNAS provided strong evidence of extensive SARS-CoV-2 infection of white-tailed…
-
Anixa Biosciences and MolGenie announced early potency analysis of SARS-CoV-2 protease inhibitor
On Jan. 24, 2022, Anixa Biosciences announced that the company and its partner, MolGenie, had synthesized a compound…
-
Biotechnology | COVID-19 | NIH | Therapeutics
‘Ultrapotent’ antibodies neutralized SARS-CoV-2 variants in NIAID study
On Jan. 20, 2022, scientists from the National Institute of Allergy and Infectious Diseases (NIAID) announced that they…
